🧬 Endocrinology Update: Mounjaro, Cell Therapy, Diabetes Tech & More
From cutting-edge cell therapy for Type 1 diabetes to AI platforms saving millions in Medicare, this week’s endocrinology update is packed with innovation. 🚀
📌 In This Episode: ✔️
Breakthrough T1D report calls for urgent cell therapy-based solutions
✔️ Mounjaro KwikPen launches across Canada with all six dose options
✔️ AI-powered PropheSee saves over $10 million in Medicare diabetes care
✔️ Glucotrack receives approval to begin long-term implantable CGM study in Australia
✔️ UW researchers identify brain neurons as a new target for Type 2 diabetes treatment
✔️ Sernova’s Cell Pouch helps two-thirds of trial patients achieve insulin independence
✔️ PolyNovo shares rise 10.5 percent after wound healing success in NovoSorb trial
✔️ Machine learning models predict GDM to T2D transition with high accuracy (AUC up to 0.92)
✔️ Only 43 percent of pregnancies meet thyroid screening guidelines; key risk factors often missed
✔️ PCOS found to raise hypertension risk by 40 percent, driven by insulin resistance
✔️ HELIOS trial shows AMX0035 improves symptoms in Wolfram Syndrome over 48 weeks
✔️ TransCon PTH Delivers Sustained Long-Term Benefits in Hypoparathyroidism
📢 Stay Ahead in Endocrinology Research!
âś… Like, share, and subscribe for weekly updates on diabetes, thyroid, hormone disorders, and rare endocrine conditions
âś… Visit www.lqventures.com for expert healthcare insights and consulting servicesÂ